Cynata Therapeutics Limited (AU:CYP) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Cynata Therapeutics Limited has requested a trading halt on its securities on the ASX, pending an announcement about the results of its Phase 1 clinical trial for diabetic foot ulcers. The halt will remain until the announcement is made or normal trading resumes on December 6, 2024. This development is likely to attract investor attention as Cynata continues to advance its stem cell therapy platform.
For further insights into AU:CYP stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue